Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Ventricular Dysfunction 1Radiation Pneumonitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hypertension 1Essential Hypertension 1Cardiotoxicity 1Barrett Esophagus 1

Interventions

Doxorubicin 17Echocardiography 14Exercise 9Cyclophosphamide 9Trastuzumab 8Dexrazoxane 8Electrocardiography 7Razoxane 6Carvedilol 6Vincristine 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cisplatin 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Enalapril × Clear all
NCT00003070 2014-08-05

Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

Children's Oncology Group

Phase 3 Completed
13 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡